Efficient systemic treatment of dystrophic muscle pathologies
US12023366B2 · kind B2 · utility
0Cited by
2References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 24, 2020 |
| Grant date | Jul 2, 2024 |
| Priority date | — |
| Expiry date | Dec 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/007
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein:the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;the composition is systemically administered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.